welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
study id #: NCT00140894
condition: Adenomatous Polyposis Coli
status: terminated
purpose:A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
intervention:
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks
expertly curated content related to this topic
-
BCIR – Olympia Medical Center Los Angeleshttps://www.youtube.com/channel/UCEdZLy_...
-
Pharmacotherapy for Inherited Colorectal CancerIMPORTANCE OF THE FIELD : An important r...
-
A New Technique for Delivering a Polyglycolic Acid Sheet to Cover a Large Mucosal Defect: The Swiss Roll MethodEndoscopic tissue shielding with polygly...
-
Aspirin and Familial Adenomatous Polyposis: Coming Full CircleThis perspective discusses the clinical ...
-
Total Proctocolectomy with Brooke Ileostomyhttp://rlv.zcache.ca/total_proctocolecto...
-
Desmoid Tumors do not Prevent Proctectomy following Abdominal Colectomy and Ileorectal Anastomosis in Patients with ...BACKGROUND: Elective proctocolectomy ha...
-
Clinical and Genomic Influence of Sulindac on Rectal Mucosa in Familial Adenomatous PolyposisPURPOSE : A study was performed to evalu...